Skip to main content

Table 2 Compliance and persistence measures of users naïve to disease-modifying agents

From: Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study

  Fingolimod Interferon beta-1b Intramuscular interferon beta-1a Subcutaneous interferon beta-1a Glatiramer acetate
  N=96 N=167 N=313 N=257 N=592
    p-value   p-value   p-value   p-value
PDC: mean (SD) 0.80 (0.23) 0.65 (0.31) <0.0001 0.72 (0.30) 0.0027 0.67 (0.31) <0.0001 0.72 (0.29) 0.0017
PDC Categories (%)    0.0003   0.0347   0.0043   0.0127
 0-<0.2 3.13 11.38   8.63   13.62   6.93  
 0.2-<0.4 7.29 16.77   10.86   12.45   11.49  
 0.4-<0.6 4.17 12.57   10.54   8.95   13.51  
 0.6-<0.8 18.75 17.37   18.53   15.56   14.02  
 0.8-1 66.67 41.92   51.44   49.42   54.05  
MPR: mean (SD) 0.90 (0.09) 0.86 (0.17) 0.0055 0.88 (0.16) 0.0502 0.88 (0.15) 0.0551 0.89 (0.15) 0.1769
MPR Categories (%)    0.0349   0.1255   0.3037   0.2619
 0-<0.2 0.00 0.62   0.68   0.41   0.36  
 0.2-<0.4 0.00 1.85   1.69   1.24   1.79  
 0.4-<0.6 1.05 8.02   6.78   4.96   5.02  
 0.6-<0.8 11.58 16.67   11.53   13.22   11.29  
 0.8-1 87.37 72.84   79.32   80.17   81.54  
Persistence (<60 day gap) (%) 68.75 46.11 0.0004 53.67 0.0090 55.25 0.0218 56.25 0.0213
Persistent days (days till first 60-day gap) (%)          
 No gap 68.75 46.11   53.67   55.25   56.25  
 1-90 6.25 16.77   14.38   18.68   13.68  
 91-180 9.38 14.37   10.22   12.06   11.82  
 181-270 8.33 14.37   13.74   8.56   10.98  
 270+ 7.29 8.38   7.99   5.45   7.26  
Switched to other DMTs after discontinuation (%) 1.04 13.17 0.0008 7.99 0.0147 11.67 0.0017 7.77 0.0153
  1. P-values based on comparison with fingolimod cohort, using Chi-square tests for categorical variables and Student’s t-tests for continuous variables.
  2. DMT: disease-modifying therapy. SD: standard deviation. PDC: proportion of days covered. MPR: medication procession ratio.